Table 2 The selected HTL epitopes for the final vaccine construction are provided by the NetMHC II pan 3.2 and IEDB server.

From: Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer

Proteins/epitopes (position)

HLA class II alleles

Antigenicity/allergenicity

Toxicity

Epitope conservation (%)

Homology to human proteins

Spike/GINITRFQTLLALHR (232–246)

HLA-DRB5*01:01, HLA-DRB1*04:04, HLA-DRB1*01:01, HLA-DRB1*11:01, HLA-DRB1*04:05, HLA-DRB1*04:01, HLA-DRB1*15:01, HLA-DRB4*01:01, HLA-DRB1*07:01, HLA-DRB1*09:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*01/DPB1*04:01

0.5582 (antigen)/non-allergen

Non-toxin

100%

Non-homolog

Spike/TNSRRRARSVASQSI (676–690)

HLA-DRB1*07:01, HLA-DRB1*01:01

0.7267 (antigen)/non-allergen

Non-toxin

100%

Non-homolog

Spike/DYSVLYNLAPFFTFK (361–375)

HLA-DRB1*01:01, HLA-DRB1*04:04, HLA-DRB1*08:03, HLA-DRB1*12:01, HLA-DRB1*13:02, HLA-DRB3*02:02, HLA-DRB3*01:01, HLA-DPA1*01:03/DPB1*04:01, HLA-DPA1*01:03/DPB1*04:02, HLA-DPA1*01,03/DPB1*23:01, HLA-DQA1*01:02/DQB1*06:04, HLA-DPA1*01:03/DPB1*02:01

0.7838 (antigen)/non-allergen

Non-toxin

100%

Non-homolog

Nucleocapsid/ALALLLLDRLNQLES (218–232)

HLA-DRB4*01:01, HLA-DRB1*03:01, HLA-DRB1*11:01, HLA-DRB1*04:04, HLA-DRB1*01:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01

0.5057 (antigen)/non-allergen

Non-toxin

100%

Non-homolog

Membrane/VGLMWLSYFIASFRL (88–102)

HLA-DRB5*01:01, HLA-DRB1*04:04, HLA-DRB1*01:01, HLA-DRB1*15:01, HLA-DRB1*04:05, HLA-DRB1*07:01, HLA-DRB1*04:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*01/DPB1*04:01

0.6658 (antigen)/non-allergen

Non-toxin

100%

Non-homolog

Envelope/FYVYSRVKNLNSSRV (56–70)

HLA-DRB1*01:01, HLA-DRB1*04:04, HLA-DRB1*07:01, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*04:05, HLA-DRB1*09:01, HLA-DRB1*13:02, HLA-DRB1*15:01

0.6103 (antigen)/non-allergen

Non-toxin

100%

Non-homolog